What is Wedbush’s Estimate for ACRS Q2 Earnings?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Stock analysts at Wedbush issued their Q2 2025 earnings per share (EPS) estimates for shares of Aclaris Therapeutics in a research note issued on Wednesday, May 28th. Wedbush analyst M. Fan anticipates that the biotechnology company will post earnings per share of ($0.12) for the quarter. Wedbush currently has a “Outperform” rating and a $8.00 price target on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.82) per share. Wedbush also issued estimates for Aclaris Therapeutics’ Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.50) EPS, Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.12) EPS, FY2026 earnings at ($0.52) EPS, FY2027 earnings at ($0.35) EPS, FY2028 earnings at ($0.28) EPS and FY2029 earnings at ($1.11) EPS.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its earnings results on Tuesday, May 6th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.07. Aclaris Therapeutics had a negative return on equity of 40.26% and a negative net margin of 136.65%.

A number of other brokerages have also recently issued reports on ACRS. Cantor Fitzgerald assumed coverage on Aclaris Therapeutics in a report on Tuesday, March 18th. They issued an “overweight” rating on the stock. Scotiabank lowered their price target on Aclaris Therapeutics from $15.00 to $9.00 and set a “sector outperform” rating for the company in a research report on Friday, May 9th. HC Wainwright reissued a “buy” rating and issued a $16.00 price target (down from $20.00) on shares of Aclaris Therapeutics in a research report on Wednesday, May 14th. Finally, Wall Street Zen lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 8th. One research analyst has rated the stock with a sell rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $9.71.

Aclaris Therapeutics Stock Up 3.5%

Shares of ACRS opened at $1.46 on Friday. Aclaris Therapeutics has a 12-month low of $0.99 and a 12-month high of $5.17. The business’s fifty day moving average is $1.31 and its 200 day moving average is $2.17. The stock has a market cap of $158.09 million, a P/E ratio of -2.81 and a beta of 0.42.

Institutional Investors Weigh In On Aclaris Therapeutics

Large investors have recently added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. bought a new position in Aclaris Therapeutics in the 4th quarter worth about $23,876,000. Vivo Capital LLC bought a new position in Aclaris Therapeutics in the 4th quarter worth about $22,044,000. Rock Springs Capital Management LP boosted its stake in Aclaris Therapeutics by 125.3% in the 4th quarter. Rock Springs Capital Management LP now owns 6,204,309 shares of the biotechnology company’s stock worth $15,387,000 after purchasing an additional 3,450,814 shares during the period. RA Capital Management L.P. bought a new position in Aclaris Therapeutics in the 4th quarter worth about $11,573,000. Finally, Millennium Management LLC boosted its stake in Aclaris Therapeutics by 111.0% in the 1st quarter. Millennium Management LLC now owns 4,134,148 shares of the biotechnology company’s stock worth $6,325,000 after purchasing an additional 2,175,101 shares during the period. Hedge funds and other institutional investors own 98.34% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.